Trial Profile
LY2525623 (IL-23 Antibody) Multiple-Dose Study in Adults With Plaque Psoriasis.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs LY 2525623 (Primary) ; LY 2525623 (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- 26 Jul 2010 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 18 Mar 2010 Status changed from discontinued to suspended as reported by ClinicalTrials.gov.
- 03 Mar 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.